The low P/S ratio is likely due to investors' concerns about the company's poor revenue performance and underwhelming growth outlook. The company will need a significant change in fortune to justify a higher P/S ratio in the future.
$Fortress Biotech(FBIO.US)$$Mustang Bio(MBIO.US)$City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial 4 MINUTES AGO, 5:00 AM EST VIA BUSINESSWIRE • Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response • Nature Medicine paper highlights delivery of CAR T cell therapy directly to the brain, a technique Ci...
$Fortress Biotech(FBIO.US)$Fortress Biotech And Cyprium Therapeutics Announce $4.1M Grant From NINDS To Further ThenDevelopment Of AAV-ATP7A Gene Therapy For Menkes Disease
Fortress Biotech's low P/S ratio may be due to anticipated poor growth or falling revenue. Its forecast growth being lower than the industry average could be causing its P/S to lag behind peers. This suggests the share price may not rise significantly soon.
Fortress Biotech股票討論區
4 MINUTES AGO, 5:00 AM EST
VIA BUSINESSWIRE
• Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response
• Nature Medicine paper highlights delivery of CAR T cell therapy directly to the brain, a technique Ci...
$OptiNose(OPTN.US)$
when are the next date for $Checkpoint Therapeutics(CKPT.US)$ , $Fortress Biotech(FBIO.US)$ , and $Brainstorm Cell Therapeutics(BCLI.US)$ ?
all of these stocks currently not good fundamentally... some even minus PBV
Hope miracle happens suddenly shows up an acquisition news like $Gracell Biotechnologies(GRCL.US)$ by ...
暫無評論